Education
About Us
Working with TipRanks
Follow Us
Elekta AB (SE:EKTA.B)
:EKTA.B
Top Page
Elekta AB
(LSE:EKTA.B)
64Neutral
Elekta AB (EKTA.B) vs. S&P 500 (SPY)
Market Cap
kr18.19B
Dividend Yield5%
Average Volume (3M)1.18M
Price to Earnings (P/E)17.5
Beta (1Y)0.89
Revenue Growth-1.85%
EPS Growth-27.56%
CountrySE
Employees4,614
SectorHealthcare
Sector Strength66
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)2.72
Shares Outstanding368,587,650
10 Day Avg. Volume1,426,145
30 Day Avg. Volume1,175,468
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr62.42Price Target Upside28.86% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering6
Elekta AB Business Overview & Revenue Model
Company DescriptionElekta AB (EKTA.B) is a Swedish company specializing in the development and delivery of clinical solutions for treating cancer and brain disorders. The company operates in the healthcare sector, providing advanced radiation therapy, radiosurgery, and clinical software solutions. Elekta's core products include linear accelerators, software for treatment planning, and systems for image-guided radiation therapy, all designed to improve patient outcomes and streamline clinical workflows.
How the Company Makes MoneyElekta AB generates revenue primarily through the sale and servicing of its medical devices and software solutions to hospitals and clinics worldwide. The company's key revenue streams include the sale of linear accelerators, which are used for radiation therapy, and associated software licenses for treatment planning and management. Elekta also earns revenue from long-term service agreements, offering maintenance and support for its equipment. Significant partnerships with healthcare providers and research institutions enhance its product offerings and market reach, contributing to its earnings. Additionally, Elekta's focus on innovation and technology advancements ensures a steady demand for its products in the oncology treatment space.
Elekta AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 17.88B | 18.12B | 16.87B | 14.55B | 13.76B | 14.60B | Gross Profit |
| 6.52B | 6.78B | 6.35B | 5.44B | 5.61B | 6.14B | EBIT |
| 1.78B | 2.04B | 1.43B | 1.64B | 1.91B | 1.66B | EBITDA |
| 2.74B | 3.29B | 2.57B | 2.74B | 3.13B | 2.99B | Net Income Common Stockholders |
| 1.04B | 1.30B | 943.00M | 1.15B | 1.25B | 1.08B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.58B | 2.78B | 3.27B | 3.07B | 4.40B | 6.46B | Total Assets |
| 32.95B | 31.41B | 29.61B | 26.30B | 24.84B | 28.41B | Total Debt |
| 8.86B | 7.25B | 6.67B | 5.70B | 6.24B | 9.36B | Net Debt |
| 5.28B | 4.47B | 3.40B | 2.63B | 1.84B | 2.96B | Total Liabilities |
| 22.12B | 20.63B | 19.88B | 17.39B | 16.65B | 20.30B | Stockholders Equity |
| 10.78B | 10.77B | 9.73B | 8.91B | 8.20B | 8.11B |
| Cash Flow | Free Cash Flow | ||||
| 679.00M | 817.00M | 400.00M | 450.00M | 1.71B | 252.00M | Operating Cash Flow |
| 2.38B | 2.46B | 1.96B | 1.86B | 2.55B | 1.01B | Investing Cash Flow |
| -1.80B | -1.92B | -1.61B | -1.65B | -613.00M | -1.30B | Financing Cash Flow |
| 516.00M | -1.10B | -129.00M | -1.73B | -3.60B | 2.62B |
Elekta AB Technical Analysis
Negative
48.44
Price Trends
56.34
Negative
59.03
Negative
62.17
Negative
Market Momentum
-2.65
Negative
36.30
Neutral
62.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EKTA.B, the sentiment is Negative. The current price of 48.44 is below the 20-day moving average (MA) of 50.65, below the 50-day MA of 56.34, and below the 200-day MA of 62.17, indicating a bearish trend. The MACD of -2.65 indicates Negative momentum. The RSI at 36.30 is Neutral, neither overbought nor oversold. The STOCH value of 62.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:EKTA.B.
Elekta AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | kr994.44M | 17.60 | 18.74% | ― | 10.46% | 22.82% | |
64 Neutral | kr18.19B | 17.52 | 9.87% | 5.00% | -1.85% | -27.56% | |
51 Neutral | $5.19B | 3.13 | -40.94% | 2.95% | 17.94% | 2.00% | |
47 Neutral | kr859.26M | ― | -1.05% | ― | 16.17% | 82.09% | |
46 Neutral | kr254.77M | ― | -102.63% | ― | -0.61% | 54.19% | |
44 Neutral | kr285.45M | ― | -12.79% | ― | -6.43% | -323.52% | |
36 Underperform | kr38.14M | ― | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
SE:EKTA.B
Elekta AB
47.60
-26.43
-35.70%
SE:ACARIX
Acarix AB
0.24
>-0.01
-1.65%
SE:CRAD.B
C-Rad AB Class B
29.45
-10.05
-25.44%
SE:INTEG.B
Integrum AB Class B
13.60
-48.40
-78.06%
SE:SEDANA
Sedana Medical AB
8.65
-5.67
-39.59%
SE:HEART
Scandinavian Real Heart AB
14.50
-40.31
-73.54%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.